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Summary 
Since  CD40/CD40  ligand  (CD40Lig)  interactions  are essential in vivo for the generation of 
germinal center B  cells that express Fas  (Apo-1/CD95), we explored whether CD40 engage- 
ment may modulate Fas expression and function on human B  lymphocytes. Resting tonsil B 
cells, isolated by density gradient centrifugation, express either absent or low levels of Fas. They 
could be induced to promptly express Fas after ligation of their CD40, however, using either a 
recombinant human CD40Lig or a cross-linked anti-CD40 mAb. In contrast,  engagement of 
the B  cell antigen receptor by immobilized anti-K and -k antibodies did not turn on Fas ex- 
pression. Addition of anti-Fas mAb CH11  inhibited the later phases of CD40-induced B  cell 
growth as a result of apoptotic cell death. Furthermore, Fas ligation inhibited proliferation and 
Ig secretion of CD40-activated B cells in response to recombinant cytokines such as interleukin 
(IL)-2, IL-4, and IL-10, as well as a cytokine-rich supernatant ofphytohemagglutinin-activated 
T  cells, indicating that none of those B cell tropic factors were able to prevent the Fas-induced 
death.  Taken together, the present results show that engagement of CD40 antigen on B  cells 
induces Fas expression and sensitizes them to Fas-mediated apoptosis. The delayed functional 
response to Fas ligation after CD40 activation may represent a way to limit the size of a specific 
B cell clone that is generated during T-B cell interactions. 
T 
o  mount efficient humoral immune responses against 
the innumerable pathogens that a living organism may 
encounter, numerous specific B cell clones should be avail- 
able at any given time, consequently imposing each a very 
limited size.  The in~rnune  system must have therefore es- 
tablished  safe  systems  to  avoid  the  overrepresentation  of 
only a few clones. Accordingly,  the survival, growth,  and 
death  of cells  is highly controlled in vivo through  surface 
molecules that bind ligands which may be either soluble or 
membrane-bound  polypeptides  (1,  2).  In  particular,  the 
CD40 receptor and the Fas (Apo-1/CD95) receptor repre- 
sent  two  members of the  TNF  receptor superfamily that 
are  expressed on  several cell  types  (3-5).  Although  these 
two receptors display a comparable overall structure,  their 
triggering results in opposite effects on cell growth. While 
CD40 acts as a growth/survival trigger for B  cells  (6),  Fas 
principally acts as a death trigger for activated T  and B cells 
(7, 8). 
Ligation of the Fas molecule by functional antibodies or 
by  its  ligand  (FasLig) 1  induces  death  of  sensitive  cells 
through  an apoptotic process (9-12).  The Fas/FasLig sys- 
1Abbreviations used in this paper: CD40Lig-L cells, L cells stably  transfected 
with the human CD40Lig; FasLig, Fas ligand; PHA-sup, supematant of 
PHA-activated blood mononuclear cells. 
tem has been demonstrated to participate in the activation- 
induced death of mature T  cells that may prevent the devel- 
opment of autoreactive T  cells  and control T  cell--depen- 
dent  immune  responses  in  vivo  (13-15).  This  concept  is 
best illustrated by the lymphoproliferative and autoimmune 
disease observed in Ipr and gld mice that are deficient for Fas 
and FasLig, respectively (16-18).  Interaction between Fas- 
Lig expressed on cytotoxic T  cells  and  Fas  on target cells 
also represents a cytolysis mechanism that complements the 
perforin/granzyme pathway (19,  20). 
When  considering  mature  B  lymphocytes,  Fas  is  ex- 
pressed at high level on B  cells in germinal centers of sec- 
ondary lymphoid  organs,  where  massive B  cell prolifera- 
tion, somatic mutations within Ig variable region gene, and 
antigen-driven selection of high affnity B  cells occur (21- 
23). Germinal center B cells are characterized by their rapid 
entry into spontaneous apoptosis, a process that can be pre- 
vented by CD40 ligation but accelerated by Fas triggering 
(22,  24). In contrast, most resting B cells express no or low 
level of Fas  and  are  not prone  to  apoptosis  (22,  23,  25). 
Since CD40-CD40Lig interaction appears necessary to in- 
duce the formation of germinal centers  (26-28),  we won- 
dered  whether  CD40  activation  of B  lymphocytes  may 
modulate  Fas  expression  and  function.  Herein  we  show 
that CD40 engagement induces resting tonsil B cells to ex- 
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death  by apoptosis.  This results in inhibition of the  later 
stages  of CD40-induced B  cell growth and differentiation. 
Thus,  the function of Fas  on B  cells prevails over that  of 
CD40  and is  therefore likely to  control the  expansion of 
antigen-specific B cell clones. 
Materials  and Methods 
Cytokines, Factors, and Culture Medium.  Purified human rlL-4 
(107 U/mg) and rlL-10 (2  ￿  107  U/rag) were from Schering- 
Plough Research Institute (Kenilworth, NJ) and were used at 50 
U/ml and 50 ng/ml, respectively.  Purified human rlL-2 (Amgen 
Biologicals, Thousand Oaks, CA) was used at 10 U/ml. A condi- 
tioned medium of activated  mononuclear cells was produced by 
stimulating PBMC  (2  ￿  106  cells/M)  with  1  I.zg/ml PHA 
(Murex Diagnostics,  Dartford,  UK) for 3 d and is referred  to as 
PHA-sup. M1 cultures  were performed in RPMI  1640 medium 
supplemented  with  2  mM  L-glutamine,  10%  heat-inactivated 
FCS  (GIBCO BILL, Gaithersburg,  MD),  and 50  lag/ml genta- 
mycin (Schering-Plough, Levallois-Perret,  France). 
Antibodies.  Purified anti-Fas mAb  (IgM,  clone  CHll)  and 
FITC-conjugated anti-Fas mAb  (IgG1,  clone UB2)  were  pur- 
chased from lmmunotech (Marseille, France).  IgM control mAb 
(for bioassays) and FITC-conjugated IgG control mAbs (for flow 
cytometric  analyses) were  from  Dako  (Glostrup,  Denmark). 
FITC-conjugated anti-CD19, anti-CD20, anti-CD2, anti-CD3, 
and anti-CD14 were from Becton & Dickinson Co.  (Mountain 
View, CA). The rat anti-mouse CD8ct mAb (clone 53.6.72)  was 
a gift from Dr. A. Zlotnik (DNAX Research Institute, Palo Alto, 
CA)  and was used as culture supernatant.  Purified mAbs against 
human K and k light chain Ig were from Immunotech. 
Fibroblastic L Cells and Human CD4OLig Constructs.  Mouse fi- 
broblastic  L  cells stably  transfected  with  the  human  CD32/ 
Fc-~/ILII (CD32-L cells) have been previously described (29). For 
generation of L cells stably transfected with the human CD40Lig 
(CD40Lig-L cells), the  CD40Lig cDNA  (30) was  amplified  by 
PCIL using the following primers:  forward 5'-CGCTAACGT- 
TCTCGAGCTTTAACACAGCATGATCGAA-3 and  reverse 
5'-CATTGTGATGCGGCCGCTCAGAGTTTGAGTAAGCC- 
AAA-3', introducing Xhol  and Not1  restriction sites, respec- 
tively (restriction  sites are underlined). PCR amplification (Per- 
kin-Elmer Cetus, Oakland, CA)  was performed by 35  cycles of 
the following scheme: 1 rain denaturation at 94~  2 min anealing 
at 60~  and 3 min primer extension at 72~  The PCR product 
was then digested,  gel purified,  and cloned into the  expression 
plasmid  pME18S-neo, which  contains the  neomycin resistance 
gene.  Mouse L cells (7 X  106) were then transfected with 20 Fxg 
of the resulting expression plasmid pME 18S-neo-CD40Lig using 
electroporation (220 V, 960 laF; Gene Pulser; Bio lKad Laborato- 
ries, ILichmond, CA).  After  electroporation, neomycin-resistant 
L cells were  selected  in ILPMI  1640,  10%  FCS containing 0.5 
mg/ml G418 (GIBCO), and CD40Lig-expressing cells were fur- 
ther isolated by three rounds of sorting on a FACStarP  lus|  (Becton 
Dickinson & Co.) after staining with a CD40-Fc chimeric mole- 
cule (31). For generation of a soluble CD40Lig-mouse CD8cr fu- 
sion  protein  (CD40Lig-mCD8),  the  extracellular  region  of 
mouse CD8cx was first amplified  by reverse  transcription PCIK 
from total IKNA of the mouse T cell line CTLL-2 using the fol- 
lowing primers: forward 5'-GCTAACGTTCTCGAGGGAGAG- 
CACACCATGGCCTCA-3' and reverse 5'-GCTAACGTTCT- 
GCAGTCGACATCACAGGCGAAGTCCAATCC-3  '  introducing 
the XhoI and Pstl  sites, respectively  (sites are underlined). The 
PCR amplification  was performed as described  above.  After di- 
gestion and purification, the PCR product was cloned into the 
expression plasmid pME18S.  By the PCR reaction, a unique Sail 
site was introduced directly  adjacent to the 3' end of the CD8~ 
gene (indicated in bold).  Next, the extracellular region of human 
CD40Lig was PCIL amplified  from CD40Lig cDNA using the 
following primers:  forward  5'-GCTAACGTTGTCGACGTC- 
AGAAGGTTGGACAAGATAGAA-3' and  reverse  5'-CAT- 
TGTGATGCGGCCGCTCAGAGTTTGAGTAAGCCAAA-3', 
introducing a SalI and NotI restriction  site, respectively  (sites are 
underlined). The forward  primer in addition introduced the se- 
quence GTC (indicated in bold). PCIL reaction was perfomled as 
described  above,  and the  PCR  product was  digested,  purified, 
and cloned into the plasmid pME18S-mCDS. By this procedure, 
the mCI)8cx and hCD40Lig are cloned in frame with a linker se- 
quence of GTCGACGTC that contains both Sail and Aatll sites, 
and coding for the  peptide Val-Asp-Val.  COS  cells (7  ￿  106) 
were then transfected with 20 lag of the final expression plasmid 
pME18S-mCD8-CD40Lig using electroporation and grown  in 
RPMI 1640, 1% Nutridoma HU (Boehringer Mannheim GmbH, 
Mannheim, Germany). After 4 d of culture, COS cell supernatant 
was harvested,  centrifuged,  and filtrated on a 0.2-btm filter. This 
expressed  soluble  CD40Lig-mCD8  construct was  found to  be 
functional,  as  determined  by  its  specific  binding on  CI)40- 
expressing human B cells atier staining with FITC-conjugated rat 
anti-mCD8ot mAb (Boehringer  Mannheim) and flow cytometric 
analysis. 
B  Cell Preparations.  Total normal B cells were purified from 
tonsils as described  earlier  (32). Briefly, mononuclear cells sepa- 
rated  by  standard  Ficoll-Hypaque gradient  were  first rosetted 
with SRBC. Nonrosetting cells were further incubated with anti- 
CD2, anti-CD3, and anti-CD14 n~a~bs, and were then submitted 
to negative selection performed with magnetic beads coated with 
anti-mouse lgG (Dynabeads; Dynal, Oslo,  Norway). Purified B 
cell preparations  contained >98% B  cells and <2% T  cells and 
monocytes,  as  determined  by  staining with  FITC-conjugated 
anti-CD19,  anti-CD20,  anti-CD2,  anti-CD3,  and  anti-CD14 
mAbs,  and  fluorescence  analysis performed  with  a  FACScan  ~ 
(Becton Dickinson & Co.). Total tonsil B cells were further sepa- 
rated  according to  their size using a  discontinuous gradient of 
Percoll (Pharmacia, Uppsala, Sweden) consisting of three layers of 
Percoll solutions in a 15-ml conical tube (4 ml of 65% [1. 085 g/ 
ml], 4 ml of 55% [1.075 g/ml], and 2 ml of 35% [1.050 g/ml]). 
5 ￿  107 B cells were overlaid on the top of the gradient and cen- 
trifuged for 20 min at 550 g at 20~  B cells recovered at the in- 
terface of 35-55% layers were referred  to as low density B cells, 
and cells recovered at the interface  of 65-55% Percoll  solutions 
were referred to as high density or resting B cells. 
Analysis of Fas Expression.  Cell-surface expression of Fas mol- 
ecule  was determined on freshly isolated  or cultured B cells by 
standard  direct immunofluorescence staining with FITC-conju- 
gated anti-Fas mAb UB2 and by flow cytometric analysis with a 
FACScan  |  Nonspecific staining was detemlined using a FITC- 
conjugated IgG1 control mAb. Dead cells and fibroblastic L cells, 
used in the different culture systems, were excluded during cyto- 
metric analysis by addition of 2 txg/ml propidium iodide and ac- 
cording to their forward and right angle scatter parameters. 
Proliferation Assay.  Resting B  cells were  seeded  in  96-well 
fiat-bottom plates (Falcon Labware, Oxnard, CA) at 2 ￿  104 cells 
per  well  in  the  presence  of  5  ￿  103  irradiated  (7,500  rad) 
CD40Lig-L cells. Cytokines and antibodies were  added  at  the 
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reach a final volume of 200  pA per well. Each culture condition 
was performed in triplicate, and proliferation was determined by 
[3H]TdR uptake after pulsing cells with [3H]TdR  (0.5  IxCi per 
well, specific activity =  25 Ci/mrnol; CEA, Saclay, France) dur- 
ing the last 16 h of culture. After harvesting cells on glass-fiber fil- 
ters,  [3H]TdR  incorporation was  measured  by  standard liquid 
scintillation counting techniques. 
Measurement of Cell  Viability and Apoptosis.  Resting B  cells 
were cultured in 48-well culture plates (10  6 cells per well) over 
irradiated CD40Lig-L cells (5 ￿  104 per well). After 3 d of activa- 
tion, anti-Fas mAb CHll or IgM control mAb were added to the 
cultures at a  final concentration of 1  p,g/ml.  Cell survival and 
apoptosis were then determined on cultured B  cells collected at 
the time indicated in the text. Viable B cells were enumerated by 
Trypan blue  exclusion.  For detection of apoptosis, cultured B 
cells were gently cytospun and stained with Giemsa. For detec- 
tion of DNA fragmentation, 2  ￿  106 cultured B  cells were col- 
lected,  washed  with  cold  PBS,  and  centrifuged  in  Eppendorf 
tubes. Pellets were then lysed in proteinase K buffer, treated with 
RNase A, and samples were run on a 1.5% agarose gel containing 
0.1  Ixg/ml ethidium bromide and visualized by UV light illumi- 
nation essentially as described earlier (33). 
Ig Production.  Purified resting B  cells (2 ￿  104 cells per well) 
were cultured on irradiated CD40Lig-L cells (5  ￿  103 per well) 
with or without cytokines or antibodies added at the onset of cul- 
ture  in  a  final volume of 200  pA. After a  14-d  culture period, 
IgM,  IgG, IgA, and lgE concentrations were measured in cell- 
free supernatants by using specific ELISAs (34). 
Results 
CD40  Engagement Induces  Fas Expression  on Resting Hu- 
man  B  Cells.  Human  tonsillar B  lymphocytes  contain  a 
subpopulation of cells expressing Fas that represent 30-40% 
of total B  cells (Fig. 1 A). They are essentially low density 
germinal center B  cells (22, 23, 35). Accordingly, Fig.  1 A 
shows that the low density tonsillar B  cells obtained by Per- 
coil gradient  centrifugation  contained  40-60%  Fas  +  ceils, 
while  high  density  (resting)  B  cells  contained  ~5%  Fas  + 
cells (mean of five experiments). 
To determine the signals required for Fas induction, rest- 
ing tonsil B  cells were  cultured  on  irradiated CD40Lig-L 
cells and  Fas  expression was  determined at  different time 
points by flow cytometric analysis. As shown  in Fig.  1  B, 
CD40  activation induced B  cells to express Fas. Fas could 
be detected on the B  cell surface as early as 12 h  after CD40 
activation,  and  its expression further  increased with  time. 
All B  cells expressed Fas after 48 h with a maximal and sta- 
ble intensity between  3  and  5  d  of culture.  To  rule out a 
possible role of the fibroblastic L  cell, resting B  cells were 
cultured with a soluble human CD40Lig-mouse CDSIx fu- 
sion protein (CD40Lig-mCD8). As shown in Fig. 1 C, cul- 
turing resting B  cells for 3 d with CD40Lig-mCD8 resulted 
in induction of Fas expression whose intensity was further 
increased by cross-linking with an anti-mCD8 antibody. In 
keeping with  this,  the  culture  of resting B  ceils over un- 
transfected L  cells did not result in upregulation of Fas ex- 
pression. 
The CD40-dependent induction of Fas expression is not 
a mere indication of B  cell activation inasmuch as engage- 
ment of resting B  cell antigen receptor, using immobilized 
anti-K  and  anti-X  mAbs,  did not  turn  on  Fas  expression 
(Fig. 2),  while it induced short-term DNA  synthesis (data 
not shown). 
Cross-linking  Fas  Molecules  Inhibits  the  Later  Stages  of 
CD40-dependent  B  Cell  Proliferation.  To  determine  the 
function  of the  Fas molecule  on  CD40-activated  B  ceils, 
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Figure  1.  CD40  ligation induces 
Fas expression on  resting tonsil B 
cells.  (A)  Expression  of  Fas  on 
freshly isolated total, low density and 
high density resting tonsil B cells. (B) 
Fas expression on resting B cells cul- 
tured on irradiated CD40Lig-L cells 
for the time indicated. (C) Fas ex- 
pression on resting B cells cultured 
for 72 h in the following conditions 
(a) in medium alone; (b) in the pres- 
ence  of  soluble CD40Lig-mCD8 
(20%  COS  supematant) with  or 
without anti-mCD8  mAb; or (c) on 
untransfected irradiated L cells. Cells 
were stained with FITC-conjugated 
anti-Fas mAb UB2 and Fas expres- 
sion  (filled histograms) was  analyzed 
by flow cytometry with  a logarith- 
mic scale. Unfilled histograms repre- 
sent staining with a negative control 
mAb. 
1267  Garrone et al. CD40LIg-L cells 
I[ 
Fluorescence intensity 
antl-~/~ + 
CD32-L cells 
Fluorescence  intensity 
Figure 2.  Triggering of the B cell antigen receptor does not induce Fas 
expression on resting B cells. Resting tonsil B cells were cultured either 
on irradiated CD40Lig-L cells or in the presence of anti-K and anti-h 
mAbs (1 I~g/ml) immobilized on irradiated CD32-L cells. After 3 d of ac- 
tivation, Fas expression  was analyzed by flow cytometry as in Fig. 1. 
resting B  cells were  cultured  on  CD40Lig-L  cells in  the 
presence  of the  anti-Fas  mAb  CH11,  a  functional  IgM 
mAb that induces  cell death when  used in a  soluble form 
(10).  Increasing  concentrations  of  anti-Fas  mAb  were 
added at the  onset of the  culture,  and B  cell proliferation 
was measured by [3H]TdR uptake on day 6.  As shown in 
Fig. 3  A, anti-Fas mAb inhibited CD40-dependent  B  cell 
proliferation in  a  dose-dependent  manner,  with  an  opti- 
mum at ~0.1  Ixg/rnl anti-Fas mAb CH11,  a concentration 
that induces maximal growth  arrest and  death of sensitive 
cell lines  (3,  10).  The  time  kinetics  of [3H]TdR  uptake, 
however,  indicated  that  anti-Fas  only  weakly  affected B 
cell proliferation during the first 3  d  of culture,  while the 
late  DNA  synthesis  (days  4-9)  was  progressively blocked 
(Fig. 3  B).  Fas ligation thus antagonizes the later stages of 
CD40-dependent B  cell DNA synthesis. 
Fas  Engagement  Induces Apoptosis  of  CD40-activated  B 
Cells.  To  determine the mechanisms  through which  Fas 
ligation inhibits B  cell proliferation, anti-Fas mAb  CHll 
was added at different time points after the initiation of the 
culture  of resting  B  cells  over  CD40Lig-L  cells.  Results 
presented in Fig. 3  C  show that addition of anti-Fas anti- 
body after 3 d  of culture prevented the subsequent increase 
of [3H]TdR uptake measured from days 4 to 9. Addition of 
anti-Fas antibody on  day 5  resulted in  a  strong and  rapid 
blockade of the  CD40-initiated DNA  synthesis.  Cell via- 
bility, determined by Trypan blue dye exclusion, showed 
the  inhibition  of proliferation  to  be  mostly  the  conse- 
quence of Fas-induced cell death. Indeed, addition of anti- 
Fas mAb to B  cells preactivated for 3  d  with  CD40Lig-L 
cells resulted in  50%  dead  cells after 24  h  and  75%  dead 
cells after 48  h  of Fas ligation (mean of four experiments) 
(Fig. 3  D).  Giemsa staining performed on 3-d CD40-acti- 
vated B  cells revealed the presence of cells exhibiting mor- 
phological  features  of apoptosis  (chromatin  condensation 
and fragmentation) as early as 2  h  after anti-Fas treatment, 
and  a  4-h  contact  with  anti-Fas  mAb  resulted  in  an 
increased  incidence  of apoptotic  cells  (Fig.  4).  More- 
over,  typical "ladder" patterns  of internucleosomal DNA 
cleavage were  observed on  electrophoresis from  DNA  of 
CD40-preactivated  B  cells further  cultured  with  anti-Fas 
for 2, 4, and 6 h, but not with a control antibody (Fig. 5). 
Taken together, these results indicate that Fas triggering 
of CD40-activated  B  cells  induces  endonuclease  activity 
and death by apoptosis. 
Fas Ligation Blocks Cytokine-induced  Proliferation and lg Se- 
cretion  of  CD40-activated  B  Cells. We  further  wondered 
whether B  cell tropic factors such as IL-2, IL-4, IL-10, or a 
PHA-sup  could prevent  the  inhibitory effects  of anti-Fas 
mAb CHll  on proliferation ofCD40-activated B  cells. To 
this end, resting B  cells were cultured on CD40Lig-L cells 
in the presence of the different B  cell growth  factors, and 
[3H]TdR  uptake was measured during an  8-d culture pe- 
riod after addition of anti-Fas mAb  on  day 0  or  5  of the 
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Figure 3.  Fas ligation inhibits DNA synthesis  and in- 
duces death of CD40-activated B cells. Resting B cells 
(2  X  104  per  well)  were  cultured  on  irradiated 
CD40Lig-L cells (5 ￿  103 per well) and (-tt) with in- 
creasing concentrations of anti-Fas mAb CHll or con- 
trol IgM mAb added at the onset of the culture; (B) 
with medium or 0.1  I.Lg/ml  anti-Fas mAb or control 
mAb added on day 0; and (C) with or without 0.1 Ixg/ 
ml anti-Fas mAb added on day 3 or 5. Proliferation was 
measured by [3H]TdR incorporation after a pulse with 
[3H]TdR during the last t6 h of the culture on day 6 
(.4) or at the time indicated (B and C), and results are 
expressed as mean  -  SD of triplicate determinations. 
In each experiment, background of [3H]TdR uptake of 
CD40Lig-L cells was <500 cpm. (D) Resting B cells 
(10  6 per well) were cultured on irradiated CD40Lig-L 
cells (5 X  104 per well). On day 3,  1 txg/ml anti-Fas 
mAb or control mAb was added to the culture and via- 
ble B cells were further enumerated by Trypan blue 
dye exclusion at the time indicated. Results represent 
average of duplicate determinations. Arrows in C and 
D indicate time of antibody addition. Data presented 
are representative of at least three independent experi- 
ments. 
1268  CD40-activated B cells Express Functional Fas Figure 4.  Fas hgation  mediates apoptosis ofCD40-activated B cells. Giemsa staining of resting B cells cultured  for 3 d over CD40Lig-L cells (A) and 
then incubated with either 1 ~g/ml anti-Fas mAb CH11 for 2 h (B) or 4 h (C  0, or with 1 I~g/ml control mAb for 4 h (D). Arrows in A and C indicate a 
CD40Lig-L cell. X 1,000. 
Figure 5.  Fas ligation induces DNA fragmentation  in CD40-activated 
B cells. Resting B cells were cultured  for 3 d over irradiated CD40Lig-L 
cells. Then 1 Ixg/rnl anti-Fas mAb CH11  or 1 p.g/rnl  control mAb was 
added  to  the  cultures.  Cells  were  collected  just  before  addition  of 
antibodies  (TO) or after 2, 4, or 6 h of treatment  with antibodies.  DNA 
culture.  As  shown  in  Fig.  6,  IL-4,  IL-10,  PHA-sup,  and 
combinations  of IL-10  with  IL-2  or  IL-4,  which  all  in- 
crease  CD40-dependent  B  cell prohferation,  were  unable 
to  counteract  the anti-Fas-induced  blockade  of DNA  syn- 
thesis.  Note  that  IL-2,  which  does not enhance  the prolif- 
eration ofCD40-activated B  cells, was also unable to coun- 
teract the effect ofanti-Fas mAb. 
To  further  analyze  whether  Fas  ligation  affected  B  cell 
differentiation,  high  density  B  cells  were  cultured  over 
CD40Lig-L cells with either PHA-sup or a combination of 
IL-10 and  IL-2, which induces massive IgA, IgG, and  IgM 
secretion  (32),  or with IL-4, which allows IgE secretion af- 
ter  isotype  switch  (36).  A~  shown  in  Table  1,  addition  of 
from 2 ￿  106 cells was run on a 1.5% agarose gel and stained with etkid- 
ium bromide.  DNA molecular  weight marker  (M) is marker  VI (2,176- 
154 bp). 
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Figure 6.  Fas engagement inhibits 
DNA synthesis of CD40-activated B 
cells  in  response  to  B  cell  growth 
factors.  Resting B cells (2 X  104 per 
well) were cultured on  CD40Lig-L 
cells  (5  X  103 per well) with either 
IL-2 (10 U/ml), IL-4 (50 U/ml), IL- 
10  (50  ng/ml), IL-2  +  IL-10,  IL-4 
4  s  6  7  8  +  IL-10,  or a  PHA-sup  (10%  final 
Time{Day)  dilution),  and  with  or without  0.1 
~g/ml  anti-Fas  mAb  CH11  added 
on day 0 or 5 of the culture. Prolif- 
PHA-sup  eration  was  measured  by  [3H]TdR 
incorporation during the last 16 h of 
the  culture  at  the  time  indicated. 
Results  are  expressed  as  means  of 
culture  triplicates.  SDs  are  not 
shown and never exceeded  10%  of 
the mean values.  [3H]TdR uptake of 
irradiated  CD40Lig-L  cells  was 
<500  cpm  in  the  different experi- 
4  S  6  ~  8  ments.  This  figure  is  representative 
Tlme (Day)  of three experiments. 
anti-Fas to cultures strongly inhibited the cytokine-induced 
secretion of IgM and IgG, as well as the IL-4-induced se- 
cretion of IgE.  A  similar inhibition of IgA secretion was 
also observed (data  not shown). Fas ligation therefore pre- 
vents the differentiation of CD40-activated B cells induced 
by IL-2  +  IL-10,  IL-4, and activated T  cell supernatants. 
Note that none of these factors were found to downregu- 
late CD40-induced Fas expression (data not shown). 
Taken together, these results indicate that neither IL-2, 
IL-4, IL-10, nor activated T  cell supernatants can antago- 
nize the Fas-induced apoptosis ofCD40-activated B cells. 
Discussion 
The  present  study  demonstrates  that  CD40  triggering 
readily turns on Fas expression on resting B  cells and that 
further Fas ligation prevails over CD40 engagement, since 
B cells that undergo the dual triggering enter into apoptosis. 
This study focused attention on the  analysis  of Fas-  B 
cells in culture that have been negatively selected by den- 
sity gradient centrifugation because positive selection (e.g., 
using antibodies to surface IgD for selecting Fas-  naive B 
cells)  could have induced subsequent alteration of Fas ex- 
pression and B  cell death/survival  (37,  38).  Maximal  Fas 
expression, reached after 48-72  h  of activation,  requires 
an  optimal  ligation  of the  CD40  molecule  that  can  be 
achieved either by CD40Lig stably expressed on fibroblas- 
tic L cells or by cross-linking a soluble CD40Lig-CD8 fu- 
sion  protein  with  anti-CD8  mAb.  Accordingly, an  anti- 
CD40 antibody had to be cross-linked with CD32-L cells 
(CD40 system) (39) for inducing Fas expression on resting 
B  cells (data  not shown).  In keeping with this, all the ex- 
periments presented herein with the CD40Lig-L cells have 
been reproduced using the CD40 system (data not shown). 
Consistent with the expression of CD40Lig on activated T 
cells  (31,  40,  41),  anti-CD3  activated  T  cells  were  also 
Table 1.  Fas Ligation Inhibits Cytokine-dependent  Ig Secretion of CD40-activated  B Cells 
Cytokine  IgM (ng/ml)  IgG (ng/ml)  IgE (ng/ml) 
Medium  IgM control  Anti-Fas  Medium  IgM control  Anti-Fas  Medium  IgM control  Anti-Fas 
None  69  53  <40  80  97  <40  <0.15  <0.15  <0.15 
IL-4  206  157  <40  208  224  <40  10.5  8.2  <0.15 
IL-10  +  IL-2  1,790  1,557  <40  1,060  1,127  <40  <0.15  <0.15  <0.15 
PHA-sup  1,253  1,181  45  3,860  3,281  50  <0.15  <0.15  <(3.15 
Resting tonsil B cells (2  X  104 per well) were cultured over irradiated CD40Lig-L cells  (5  ￿  103 per well) without or with IL-4 (50 U/ml), IL-10 
(50 ng/ml) plus IL-2 (10 U/M), or PHA-sup (10%),  as well as in the absence or presence of O. 1 ~g/ml anti-Fas mAb CH11  or an IgM control mAb. 
After 14 d of culture, cell-free supematants were collected, and the concentrations of lgM, IgG, and IgE were measured by specific ELISAs. Results 
are expressed as the mean of triplicate determinations, and they are representative of three independent experiments. SDs were < 10% in all cases. 
1270  CD40-activated B  cells Express Functional Fas found to readily induce Fas expression on B  cells  (data not 
shown). 
While considerable Fas expression could be observed af- 
ter 24-48  h  of CD40  activation,  a  functional response to 
Fas  triggering could  only be seen  after 3  d  of activation, 
since B cells costimulated through both CD40 and Fas dis- 
play reduced  growth  and the first signs  of cell death  only 
after 3  d  of culture.  Such  a  delayed  establishment of Fas 
sensitivity has been previously described for normal B  cells 
activated  with  pokeweed  mitogen  (42),  for  leukemic  B 
ceils  activated with  a  combination  of Staphylococcus aureus 
particles and  IL-2  (43),  and for mitogen-activated T  cells 
(44,  45). The cell susceptibility to Fas-mediated killing was 
previously associated with an inverse expression of the anti- 
apoptotic intracellular Bcl-2 protein (43,  46, 47). Though a 
slight decrease in Bcl-2 protein expression was observed in 
B  cells  activated for more  than  3  d  through  their  CD40 
(data not shown), this does not permit us to account for the 
susceptibility  of B  cells  to  Fas  ligation.  This may be ex- 
plained by the numerous genes that appear to be involved 
in  the  control  of cell survival (48,  49).  Thus,  a  thorough 
analysis  aimed at understanding the establishment of B  cell 
susceptibility to Fas ligation will require  the availability of 
antibodies  specific  for  these  gene  products  because  the 
death/survival  decision  depends  on  the  balance  between 
these proteins. 
An  efficient  T  cell-dependent  humoral  immune  re- 
sponse against one specific antigen is initiated when APCs 
and B  cells  present the  processed antigen  to T  cells  in an 
MHC-restricted  fashion.  T  cells  activated  through  their 
TCR./CD3  complex are induced to express CD40Lig and 
to secrete cytokines that in turn  induce  CD40-dependent 
B  cell proliferation  (6,  50).  TCR  engagement,  however, 
can induce  FasLig expression on T  cells  (13-15,  51),  and 
the present results clearly demonstrate that CD40  engage- 
ment induces Fas expression on B cells, and further ligation 
of this  inhibits  CD40-dependent  DNA  synthesis.  Thus, 
simultaneous  induction  of the  CD40/CD40Lig  and  Fas/ 
FasLig systems may result in aborted humoral immune re- 
sponses.  Several  possibilities  should  be  considered  to 
explain  how  B  cells  can  survive,  grow,  and  differentiate 
when they receive signals  from activated T  cells.  (a) Acti- 
vated  CD4 +  T  cells  may  not  always  express  FasLig.  In 
keeping with  this,  murine  Th2  cells,  which  represent the 
preferential helpers  of humoral  responses,  were  shown  to 
express no or low level of FasLig, while Thl cells represent 
potent effectors of Fas-mediated cytotoxicity (52, 53).  (b) T 
cells may deliver additional signals that may counteract Fas- 
Lig/Fas-induced B  cell death.  Inasmuch as efficient T  cell 
help required different T/B cell interactions (54),  such cell- 
surface antigen interactions have to be considered since the 
experiments reported herein do not support a possible ef- 
fect of T  cell cytokines.  (c) B  cell antigen  receptor signals 
may limit sensitivity to  Fas ligation,  thus  favoring expan- 
sion and differentiation of antigen-specific B cells and pre- 
venting expansion of bystander activated B  cells.  This was 
recently described in an analysis  of mouse B  cell suscepti- 
bility  to  Fas-dependent,  Thl-mediated  cytotoxicity mea- 
sured in 4-h chromium release assays (55).  Our preliminary 
data  indicate  that  surface  Ig triggering  on  resting  B  cells 
downregulates  CD40-induced  Fas  expression and partially 
prevents further Fas-induced  cell death  (data  not shown). 
(d)  Functional  Fas/FasLig interaction may represent a late 
event in the T/B  cell dialog. While  Fas  is expressed early 
on activated B  cells,  their sensitivity towards  Fas-induced 
death is acquired only after prolonged activation (reference 
42 and our present results).  Thus, during T  cell encounter, 
an antigen-selected B cell (e.g., in the germinal center light 
zone) will undergo CD40 activation that leads to clonal ex- 
pansion and seeding of daughter B cells that will eventually 
differentiate into plasma blasts and/or memory B cells (56). 
The initial B  cell of the clone will then be eliminated by 
apoptosis after a  prolonged Fas  engagement.  The  CD40- 
induced upregulation of Fas expression, associated to a de- 
layed functional FasLig responsiveness, may therefore rep- 
resent a way to limit the expansion of a given B cell clone. 
A  dysfunction of this Fas system will result in the genera- 
tion  of a  predominant  clone  that  will  compete with  the 
multiple B cell clones required for appropriate humoral re- 
sponses.  Complementary findings  on  the  upregulation  of 
functional  Fas  expression  on  B  lymphocytes  activated 
through their CD40 antigen have been reported in two re- 
cent studies (57,  58). 
In conclusion,  CD40  triggering turns on Fas  expression 
on B  cells  that undergo apoptosis after subsequent Fas en- 
gagement.  The Fas system may thus  represent a safeguard 
system that operates not only on T  cells,  but also at the B 
cell level, and may permit to limit the B cell clone size dur- 
ing T  cell-dependent humoral immune responses. 
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